Employees: 211
Size Shukra Pharmaceuticals (SHUKRAPHAR.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $387M, the 964th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹82.20 on 18 Nov 2026.
Growth Revenue grew 222.3% over the last twelve months (peer median -8.0%); the operating margin is 54.5% (peer median -13.4%).
Valuation It trades at 32.0× enterprise value to sales against a peer median of 4.9× (5th most expensive of 18).
Capital Return on invested capital runs 26.0 points above its cost of capital (9.4% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹1.13B | ₹567M | ₹326M | ₹746M | ₹588M |
| Revenue growth | — | +74% | -56% | +27% | — |
| Gross profit | ₹699M | ₹306M | ₹156M | ₹230M | ₹66.1M |
| EBITDA | ₹657M | ₹290M | ₹127M | ₹195M | ₹64.6M |
| Net income | ₹443M | ₹220M | ₹95.8M | ₹185M | ₹44.1M |
| Free cash flow | n/a | -₹120M | ₹60.6M | -₹66.8M | -₹15.1M |
| Capital expenditure | n/a | ₹157M | ₹27.4M | ₹17.6M | ₹44.9M |
| Total debt | ₹225M | ₹50.2M | ₹41.8M | ₹31.5M | ₹50.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SHUKRAPHAR.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +19.8% | -13.1% | highest of 20 |
| Distance from 52-week high | -3.1% | -44.6% | highest of 21 |
| Revenue growth (TTM) | +222.3% | -8.0% | highest of 18 |
| Operating margin | 54.5% | -13.4% | highest of 19 |
| EV / Sales | 32.0× | 4.9× | 5th most expensive of 18 |
| ROIC minus cost of capital | +26.0 pp | -7.3 pp | 3rd highest of 17 |
| EV / EBITDA | 55.2× | n/a | — |
| Net debt / EBITDA | 0.2× | -2.9× | 2nd most indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shukra Pharmaceuticals SHUKRAPHAR.NS | India | $387M | n/a | +222% | 54% | 32.0× | n/a | n/a |
| iX Biopharma 42C.SI | Singapore | $387M | +28% | -12% | -140% | 71.6× | n/a | n/a |
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $386M | -2% | -21% | 8% | 3.7× | 20.9% | +28.2% |
| Avalo Therapeutics AVTX | United States | $387M | -59% | -69% | -161,961% | n/a | n/a | n/a |
| SanBio 4592.T | Japan | $386M | -55% | n/a | n/a | n/a | n/a | n/a |
| Anhui Sunhere Pharmaceutical Excipients 300452.SZ | China | $388M | -17% | +9% | 19% | 2.2× | -5.5% | +12.2% |
| Lifecome Biochemistry 002868.SZ | China | $384M | -54% | -23% | -3% | 6.2× | n/a | n/a |
| Heartseed 219A.T | Japan | $392M | +53% | +197% | 9% | 21.9× | 46.5% | +73.2% |
| JCR Pharmaceuticals 4552.T | Japan | $379M | -5% | +3% | -14% | 2.9× | n/a | n/a |
| Opus Genetics IRD | United States | $379M | -22% | -46% | -778% | 41.2× | n/a | n/a |
| Jiangxi Synergy Pharmaceutical 300636.SZ | China | $398M | -13% | -3% | 2% | 3.4× | 14.9% | +13.7% |
| Jiangsu Bioperfectus Technologies 688399.SS | China | $374M | -51% | -8% | -23% | 4.4× | n/a | n/a |
| Puma Biotechnology PBYI | United States | $373M | +3% | +9% | 11% | 1.2× | 0.1% | +0.3% |
| ARS Pharmaceuticals SPRY | United States | $371M | -53% | -14% | -162% | 2.9× | n/a | n/a |
| Tiansheng Pharmaceutical 002872.SZ | China | $371M | -1% | -1% | -13% | 4.9× | 22.2% | -15.7% |
| MapLight Therapeutics MPLT | United States | $370M | -76% | n/a | n/a | n/a | n/a | n/a |
| Shandong Sinobioway Biomedicine 002581.SZ | China | $405M | -24% | +91% | -65% | 7.9× | n/a | n/a |
| Beijing Centergate Technologies (Holding) 000931.SZ | China | $406M | -18% | -16% | 2% | 1.9× | 9.2% | +6.7% |
| 6467 6467.TW | Taiwan | $368M | n/a | n/a | -2,618% | 1,407.9× | n/a | n/a |
| Lumosa Therapeutics 6535.TWO | Taiwan | $406M | -37% | -25% | -803% | 399.1× | n/a | n/a |
| Guangdong Lifestrong Pharmacy 301111.SZ | China | $368M | -33% | +7% | -2% | 7.2× | n/a | n/a |